2010 Prix Galien winners include Merck & Co, Novartis, Amgen and Bayer
Scholarly papers from the winners and finalists of the 2010 Prix Galien USA and Prix Galien International awards have been published as a special issue of Annals of the New York Academy of Sciences. The Prix Galien, regarded as the Nobel Prize in biopharmaceutical research, recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and treatments.
Established in 1970, Prix Galien is the most prestigious award of its kind in eleven countries. The awards include the Prix Galien Humanitarian Award, the International Prix Galien award, and Prix Galien USA, which has three sub-categories, Best Medical Technology, Best Pharmaceutical Agent and Best Biotechnology Product.
Awards made
Best Medical Technology was awarded to Luminex Corporation for xTAG. "Advances in the diagnosis of respiratory tract infections: role of the Luminex xTAG respiratory viral panel" led by Nancy Krunic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze